TransMedics Group (TMDX) Prices Upsized 3.25M Share Offering at $40/sh

TransMedics Group, Inc. (Nasdaq: TMDX) announced today the upsize and pricing of an underwritten public offering of 3,250,000 shares of its common stock at a price to the public of $40.00 per share. All of the shares are being offered by TransMedics.

The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by TransMedics, are expected to be $130 million. The offering is expected to close on August 9, 2022, subject to the satisfaction of customary closing conditions. In addition, TransMedics has granted the underwriters a 30-day option to purchase up to an additional 487,500 shares of common stock at the public offering price, less underwriting discounts and commissions.

J.P. Morgan, Morgan Stanley and Cowen are acting as joint lead book-running managers for the offering. Canaccord Genuity is acting as lead manager for the offering.

The securities described above are being offered by TransMedics pursuant to its automatically effective shelf registration statement on Form S-3ASR filed with the Securities and Exchange Commission (the "SEC") on August 3, 2022. Before you invest, you should read the prospectus in the registration statement and related prospectus supplement for more complete information about TransMedics and this offering. An electronic copy of the preliminary prospectus supplement and accompanying prospectus relating to the offering are available on the SEC's website at www.sec.gov. An electronic copy of the final prospectus supplement and accompanying prospectus will be available on the SEC website at www.sec.gov or, when available, may also be obtained from J.P. Morgan Securities LLC, c/o J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone, at (866) 803-9204; from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; or from Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (833) 297-2926, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• Vincerx Pharma (VINC) Announces Proposed Share and Warrant Offering
• INmune Bio (INMB) Prices 986K Share Offering at $9.84/sh
• Belite Bio (BLTE) Announces $25 Million Registered Direct Offering